Nature Cell Biology:瑞金医院发现肥胖治疗新靶标LGR4基因

2013-12-26 佚名 中国科学报

记者从上海交大医学院附属瑞金医院获悉,该院内分泌科宁光研究团队日前发现了一个肥胖发生与治疗的新靶标——LGR4基因。研究显示,上述基因的缺失可促进白色脂肪转化为棕色脂肪,增加机体能量消耗,减轻体重。相关研究成果发表于《自然细胞生物学》。 “肥胖是由人体内白色脂肪组织过度堆积所致。”宁光解释说,人体有两种脂肪组织:白色脂肪和棕色脂肪。白色脂肪将能量以甘油三酯形式储存起来

记者从上海交大医学院附属瑞金医院获悉,该院内分泌科宁光研究团队日前发现了一个肥胖发生与治疗的新靶标——LGR4基因。研究显示,上述基因的缺失可促进白色脂肪转化为棕色脂肪,增加机体能量消耗,减轻体重。相关研究成果发表于《自然细胞生物学》。【原文下载】

“肥胖是由人体内白色脂肪组织过度堆积所致。”宁光解释说,人体有两种脂肪组织:白色脂肪和棕色脂肪。白色脂肪将能量以甘油三酯形式储存起来;棕色脂肪将能量以热的形式散失掉。最新研究表明,成年人体内也存在棕色脂肪,使得棕色脂肪成为减肥的潜在器官。

宁光研究团队通过对大样本肥胖患者的LGR4基因进行测序发现,如果LGR4基因发生激活变异,人类肥胖患病风险将增加2倍以上;进一步,如果在小鼠体内敲除这个LGR4基因,那么小鼠体重就会减轻。

研究人员王计秋介绍说:“我们发现,高脂诱导下的小鼠在LGR4基因被敲除之后,能量消耗和基础代谢率明显增加,致使其体脂含量和体重均明显减轻,各项代谢指标,包括血糖、血脂、血压等,均明显好转。”

业内专家表示,这项结果为临床肥胖干预提供了一个全新方向。

原文出处:

Jiqiu Wang,Ruixin Liu,Feng Wang,Jie Hong, Xiaoying Li, Maopei Chen, Yingying Ke, Xianfeng Zhang,Qinyun Ma,Rui Wang,Juan Shi, Bin Cui,Weiqiong Gu, Yifei Zhang,Zhiguo Zhang,Weiqing Wang,Xuefeng Xia,Mingyao Liu & Guang Ning.Ablation of LGR4 promotes energy expenditure by driving white-to-brown fat switch.Nature Cell Biology ,10 November 2013, doi:10.1038/ncb2867【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1766857, encodeId=090c1e66857d3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jan 21 19:43:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958983, encodeId=4693195898392, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 19 22:43:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879809, encodeId=abbd18e9809ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 21 07:43:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917005, encodeId=7027191e00548, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 03 20:43:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868742, encodeId=f3dc1868e4202, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 20 23:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025292, encodeId=103e202529294, content=<a href='/topic/show?id=45dc10858df' target=_blank style='color:#2F92EE;'>#LGR4基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10858, encryptionId=45dc10858df, topicName=LGR4基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Nov 22 06:43:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352716, encodeId=903e1352e16f1, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 28 00:43:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1766857, encodeId=090c1e66857d3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jan 21 19:43:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958983, encodeId=4693195898392, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 19 22:43:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879809, encodeId=abbd18e9809ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 21 07:43:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917005, encodeId=7027191e00548, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 03 20:43:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868742, encodeId=f3dc1868e4202, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 20 23:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025292, encodeId=103e202529294, content=<a href='/topic/show?id=45dc10858df' target=_blank style='color:#2F92EE;'>#LGR4基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10858, encryptionId=45dc10858df, topicName=LGR4基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Nov 22 06:43:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352716, encodeId=903e1352e16f1, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 28 00:43:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]
    2014-04-19 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1766857, encodeId=090c1e66857d3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jan 21 19:43:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958983, encodeId=4693195898392, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 19 22:43:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879809, encodeId=abbd18e9809ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 21 07:43:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917005, encodeId=7027191e00548, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 03 20:43:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868742, encodeId=f3dc1868e4202, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 20 23:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025292, encodeId=103e202529294, content=<a href='/topic/show?id=45dc10858df' target=_blank style='color:#2F92EE;'>#LGR4基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10858, encryptionId=45dc10858df, topicName=LGR4基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Nov 22 06:43:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352716, encodeId=903e1352e16f1, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 28 00:43:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]
    2014-09-21 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1766857, encodeId=090c1e66857d3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jan 21 19:43:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958983, encodeId=4693195898392, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 19 22:43:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879809, encodeId=abbd18e9809ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 21 07:43:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917005, encodeId=7027191e00548, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 03 20:43:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868742, encodeId=f3dc1868e4202, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 20 23:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025292, encodeId=103e202529294, content=<a href='/topic/show?id=45dc10858df' target=_blank style='color:#2F92EE;'>#LGR4基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10858, encryptionId=45dc10858df, topicName=LGR4基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Nov 22 06:43:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352716, encodeId=903e1352e16f1, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 28 00:43:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]
    2014-11-03 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1766857, encodeId=090c1e66857d3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jan 21 19:43:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958983, encodeId=4693195898392, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 19 22:43:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879809, encodeId=abbd18e9809ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 21 07:43:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917005, encodeId=7027191e00548, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 03 20:43:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868742, encodeId=f3dc1868e4202, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 20 23:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025292, encodeId=103e202529294, content=<a href='/topic/show?id=45dc10858df' target=_blank style='color:#2F92EE;'>#LGR4基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10858, encryptionId=45dc10858df, topicName=LGR4基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Nov 22 06:43:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352716, encodeId=903e1352e16f1, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 28 00:43:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1766857, encodeId=090c1e66857d3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jan 21 19:43:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958983, encodeId=4693195898392, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 19 22:43:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879809, encodeId=abbd18e9809ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 21 07:43:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917005, encodeId=7027191e00548, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 03 20:43:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868742, encodeId=f3dc1868e4202, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 20 23:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025292, encodeId=103e202529294, content=<a href='/topic/show?id=45dc10858df' target=_blank style='color:#2F92EE;'>#LGR4基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10858, encryptionId=45dc10858df, topicName=LGR4基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Nov 22 06:43:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352716, encodeId=903e1352e16f1, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 28 00:43:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1766857, encodeId=090c1e66857d3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jan 21 19:43:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958983, encodeId=4693195898392, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 19 22:43:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879809, encodeId=abbd18e9809ae, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 21 07:43:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917005, encodeId=7027191e00548, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 03 20:43:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868742, encodeId=f3dc1868e4202, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 20 23:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025292, encodeId=103e202529294, content=<a href='/topic/show?id=45dc10858df' target=_blank style='color:#2F92EE;'>#LGR4基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10858, encryptionId=45dc10858df, topicName=LGR4基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Nov 22 06:43:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352716, encodeId=903e1352e16f1, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 28 00:43:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]
    2013-12-28 zhaojie88

相关资讯

APJN:正常代谢水平之肥胖状态在台湾之盛行率及其对于高血压、糖尿病和代谢症候群发生率的影响

肥胖是与代谢疾病和心脏血管疾病罹病率及死亡率密切相关之流行性健康问题。然而,对于具有正常代谢水平之肥胖状态,其罹患代谢疾病和心脏血管疾病的危险性所知有限。本研究是以具有全国代表性之研究世代为研究个案,探讨具有正常代谢水平之肥胖状态盛行率及其对于代谢疾病和心脏血管疾病发生率的影响。 【原文下载】 纳入分析之研究个案数为1,547 人(年龄介于18-59 岁)。

JBJS:肥胖患者肩关节置换术后效果优良

在美国,肥胖人群越来越多,而肥胖通常被认为是慢性疾病如糖尿病、心脏病、中风等诸多疾病的危险因素,会给个人及社会带来沉重的经济负担。关于肥胖患者进行髋、膝关节置换手术的文献报道很多,有些报道认为肥胖患者的医疗费用、围手术期并发症、感染和关节返修率相对增多,但也有人持不同观点研究认为肥胖患者和正常体重的患者在最终疗效没有差别。 围绕肥胖患者进行肩关节置换手术的研究并不多,

肥胖会增加女性听力丧失风险

肥胖的女性要注意了。据《印度快报》11月26日报道,美国布莱根女子医院的研究人员发现,肥胖会增加女性听力丧失的风险。通常认为,听力功能下降是人体老化过程中不可避免的一部分,但这项研究成果表明,如果保持适当的体重,这个衰老过程可能会减慢。 研究人员选取了近7万名女性的资料,从1989~2009年间对她们进行了随访。这些数据资料包括她们的身高体重指数、腰围、体育活动量和自

肥胖相关性肾病

随着人们物质生活水平的提高和生活方式的改变肥胖已成为危害人类健康的严峻问题在美国从上世纪60年代至2004年成人肥胖的发病率从13%增至32%至2004年美国有66%成人和16%儿童和青少年属于超重或肥胖。 中国的肥胖情况也不容乐观根据中国家庭营养健康调查数据从1993年2009年男性肥胖比例从2.9%增至11.4%女性从5.0%增至10.1%。 肥胖作为一种特殊的疾病状态会促进多种疾病的

Ann Intern Med:肥胖者即使代谢正常 其远期不良转归风险也高

加拿大一项荟萃分析表明,与代谢正常体重正常者相比,即便在无代谢异常的情况下,肥胖者的远期不良转归风险亦升高。论文发表于《内科学年鉴》[Ann Intern Med. 2013, 159(11):758]。 研究者检索了相关电子数据库,并纳入了在6类患者中评估全因死亡、心血管事件和临床特征的研究。6类患者由BMI分类(正常体重/超重/肥胖)和代谢状况(正常/异常)加以定义。在正常体重、超重和肥胖患